
There may be differences between this version and the published version. You are advised to consult the publisher’s version if you wish to cite from it.

http://eprints.gla.ac.uk/165354/

Deposited on: 24 July 2018
ARE THE AHA/ACC HIGH BLOOD PRESSURE GUIDELINES FIT FOR GLOBAL PURPOSE?

THOUGHTS FROM THE INTERNATIONAL SOCIETY OF HYPERTENSION (ISH).

Short Title: The ISH slant on the AHA/ACC BP Guidelines.

N R Poulter, Imperial Clinical Trials Unit, Imperial College London, London, UK.

R Castillo, Section of Cardiovascular Medicine, Faculty of Medicine, Adventist University of the Philippines; Manila Doctors’ Hospital, Manila, Philippines.

F J Charchar, Faculty of Science and Technology, Federation University Australia, Ballarat, Victoria, Australia.

M P Schlaich, Dobney Hypertension Centre, University of Western Australia-Royal Perth Hospital, Australia.

A E Schutte, Hypertension in Africa Research Team (HART), SAMRC Unit for Hypertension and Cardiovascular Disease, North-West University, Potchefstroom, South Africa.

M Tomaszewski, Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.

R M Touyz, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.

J Wang, The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.

Corresponding Author: Professor Neil R. Poulter, Imperial College London, Stadium House, 68 Wood Lane, London, W12 7TA.

Contact: 0207 594 3445
Email: n.poulter@imperial.ac.uk

Word count: 2102
In 2017 the American College of Cardiology (ACC), the American Heart Association (AHA) and nine other American societies released guidelines for the prevention, detection, evaluation and management of high blood pressure (BP) in adults.¹

These guidelines are perhaps the most controversial set of US guidelines – even more so than those attributed to some of the committee set up to produce “JNC 8” in 2014.²

Before discussing the various controversial aspects of the ACC/AHA guidelines, ISH would like to congratulate the authors on three counts. Firstly, emphasis was placed on the appropriate technique of BP measurements and the increased need for out-of-office BP measurement. Secondly the value of risk assessment was recognised and introduced for the first time in US guidelines and finally, perhaps in part due to the controversial nature of the document, awareness of the importance of BP as a global cause of morbidity and mortality has been raised.

The central controversy around which several others arise is the redefining of hypertension – as a systolic BP >130 mmHg or a diastolic BP >80 mmHg. Whilst there is a clear dose-response relationship between increasing BP levels and adverse cardiovascular (CV) outcomes³, this pre-empts the ability, based on predicting CV events, of precisely defining ‘hypertension’. However, the pragmatic definition proposed by Geoffrey Rose decades ago should perhaps be considered – viz: “that level of BP above which investigation and management does more good than harm”.⁴ Does the new BP level proposed in the ACC/AHA guidelines fully satisfy that criterion? Perhaps not. To date the relevant data are inconsistent and hence controversial.

The problem arises because the definition of hypertension, treatment thresholds and BP targets should be inexorably linked, if we are to be logical about diagnosis and treatment.
It seems likely that the new ACC/AHA definition arose, in large part, from the results of the SPRINT trial. The ACC/AHA authors have apparently modified the systolic BP target of <120 mmHg established as superior in the SPRINT trial, in light of concerns over the method of measurement used and set a systolic BP of <130 mmHg as the target BP. This makes the setting of the treatment threshold difficult unless target and threshold are to be dissociated. Inevitably, if threshold and target unite, the definition of hypertension follows on as a systolic BP >130 mmHg.

However, as a multinational society whose role is to present a global perspective, the ISH is concerned at the impact of redefining hypertension in countries around the world – particularly those of low and middle income.

The reality for most of the world is that BP control rates (to <140 mmHg and <90 mmHg) are <15%. Surely this is not the time to impose a huge increase in hypertension prevalence by redefining it, particularly when the data regarding optimal targets are inconsistent and hence remain subject to debate.

In an article written prior to publication of the ACC/AHA guidelines, the ISH provided a global perspective on BP thresholds and targets. We concluded that whilst the data were (and still are) by no means definitive, in an ideal world, where resources allow, and in the interest of simplicity a systolic target of 130 mmHg could reasonably be set for people with or without diabetes. However, we acknowledged that thresholds as low as 140 mmHg may be inappropriately low, which is supported by some current guidelines, that recommend that treatment may not be indicated for low risk patients with a systolic BP below 160 mmHg.
Pending more definitive information we believe focus should be placed on improving BP awareness\textsuperscript{15} and once hypertension is diagnosed, ensuring that effective, low-cost, evidence-based medicines are available to lower BP to current targets (<140/90 mmHg).\textsuperscript{6,16} Only as resources allow might the systolic target of 130 mmHg be invoked and then possibly only for those at highest CV risk.

We believe that even through the ideal systolic BP target may be 130 mmHg the standard definition of hypertension should not change and to square the circle of having a mismatch between definition and target, those with systolic BPs between 130-139 mmHg should be labelled as “high normal” or “pre-hypertensive” (as per the JNC 7 guidelines).\textsuperscript{17} All such people should receive non-pharmacological advice and as resources allow drug therapy could be initiated for those at highest risk including those with a history of established CV disease.

The global uptake of the newly-proposed hypertension definition seems unlikely and may be inappropriate. Even in the US, two major societies, the American Academy for Family Physicians and the American College of Physicians have raised concerns about potential harm associated with implementing the ACC/AHA guidelines\textsuperscript{18} and others have suggested that no likely benefit in terms of cost-efficacy might accrue.\textsuperscript{19}

Elsewhere around the world, recommended BP levels differed in eight of 14 comparisons of thresholds and targets for patient subgroups in ACC/AHA versus Canadian guidelines\textsuperscript{20} and in the Australian NHF guidelines\textsuperscript{21} all 11 direct comparisons of thresholds and targets differ from those in the ACC/AHA guidelines. This is not to say that any of these three sets of guidelines are correct, but rather to highlight that there is no consensus about these data.
The concerns raised regarding the new ACC/AHA definition of hypertension and the associated clinical fallout include the dangers of inappropriately labelling people as hypertensive and thereby causing anxiety, and over-inflated hypertension treatment in low risk younger people (especially women) who get caught up in the newly-enhanced ‘hypertensive’ population for whom evidence of treatment benefit is not yet established.

Other issues that we believe reflect the lack of suitability of the ACC/AHA guidelines for exportation to most of the world, include the recommended method of unattended clinic BP measurement which, whilst it has undoubted benefits, is aspirational in most of the world. In addition, the idea that adults with “stage 2 hypertension” – hitherto defined as mild or stage 1 hypertension – should be seen within one month of diagnosis and at that time receive two agents as “first-line” therapy lacks a robust evidence base. Furthermore, that follow-up for such patients should occur in one month after initiating therapy is an unrealistic expectation for the vast majority of the world and, given that most agents - alone or in combination - usually produce maximal BP-lowering effects well after four weeks is probably unnecessarily soon.
Funding Sources: None

Conflicts of Interest/Disclosures Statements

Neil R Poulter has received financial support from several pharmaceutical companies which manufacture BP-lowering agents, for consultancy fees (Servier), research projects and staff (Servier, Pfizer) and for arranging and speaking at educational meetings (AstraZeneca, Lri Therapharma, Napi, Servier and Pfizer). He holds no stocks and shares in any such companies.

In the last two years, Rafael Castillo has received speaker’s honoraria from Servier, Boehringer Ingelheim, Unilab, LRI-Therapharma, Menarini, and Torrent Pharmaceutical.

Fadi Charchar has nothing to declare.

Markus Schlaich is supported by an NHMRC Research Fellowship and has received consulting fees, and/or travel and research support from Medtronic, Abbott, Novartis, Servier, Pfizer and Boehringer-Ingelheim.

Aletta E Schutte has no conflicts to declare. She is funded by the South African Medical Research Council and the South African Department of Science and Technology (SARChI Chair Programme).

Maciej Tomaszewski has received lecture honoraria from Boehringer Ingelheim. He has no other disclosures to declare.

Rhian M Touyz is funded through a British Heart Foundation grant

Jiguang Wang has nothing to declare.
Summary:

On the basis of currently available evidence,

1. We welcome the increased emphasis on out-of-office BP measurement which the ACC/AHA guidelines provide, but advise caution on the reported equivalence levels by type of measurement.

2. We support the use of risk assessment recommended in the ACC/AHA guidelines but note that the levels recommended as defining high risk do not accurately match those used in SPRINT.

3. We welcome the increased awareness about the importance of raised BP which the ACC/AHA guidelines have raised.

4. We suggest that in the global context, the definition of hypertension should remain as systolic BP $\geq 140$ mmHg and/or diastolic BP $\geq 90$ mmHg.

5. We believe that ideal systolic BP targets for those with or without diabetes should probably be 130 mmHg. However, people with systolic BP in the range 130-139 mmHg should receive non-pharmacological advice, and only where resources allow and for those at high CV risk should drug therapy be considered for such people.
References:

   ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the
   Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. A
   Report of the American College of Cardiology/American Heart Association Task Force on
   doi.org/10.1161/HYP.0000000000000066

   of high blood pressure in adults: report from the panel members appointed to the

3. Prospective Studies Collaboration. Age specific relevance of usual blood pressure to
   vascular mortality: a meta-analysis of individual data for one million adults in 61

   801-12.


17. Aram V. Chobanian, MD; George L. Bakris, MD; Henry R. Black, MD; William C. Cushman, MD; Lee A. Green, MD, MPH; Joseph L. Izzo, Jr, MD; Daniel W. Jones, MD; Barry J. Materson, MD, MBA; Suzanne Oparil, MD; Jackson T. Wright, Jr, MD, PhD; Edward J. Roccella, PhD, MPH; and the National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure -The JNC 7 Report. *JAMA*. 2003;289(19): 2560-2571.


HYPERTENSIONAHA.118.10815